DCTH
Delcath Systems, Inc. NASDAQ Listed May 3, 2018$11.24
Pre-mkt
$11.40
-0.70%
Mkt Cap $390.5M
52w Low $8.12
30.9% of range
52w High $18.23
50d MA $9.88
200d MA $10.19
P/E (TTM)
143.2x
EV/EBITDA
82.7x
P/B
3.5x
Debt/Equity
0.0x
ROE
2.4%
P/FCF
17.3x
RSI (14)
—
ATR (14)
—
Beta
0.43
50d MA
$9.88
200d MA
$10.19
Avg Volume
417.6K
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
1633 Broadway · New York City, NY 10019 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 11.26 | +2.2% | -0.2% | +2.1% | — | — | — | — |
| Feb 26, 2026 | AMC | -0.06 | -0.05 | +20.6% | 9.00 | +0.1% | -1.1% | +0.3% | -3.7% | +7.3% | -1.6% | — |
| Nov 4, 2025 | AMC | 0.02 | 0.02 | +0.0% | 9.08 | -1.7% | -4.4% | -0.5% | +0.0% | -0.7% | +0.5% | — |
| Aug 6, 2025 | AMC | 0.03 | 0.07 | +169.2% | 10.64 | +2.3% | -4.2% | -1.8% | +5.0% | +3.5% | +2.1% | — |
| May 8, 2025 | AMC | 0.10 | 0.03 | -70.0% | 14.36 | +0.1% | +3.3% | -2.6% | +5.8% | +1.2% | +3.7% | — |
| Mar 6, 2025 | AMC | -0.10 | 0.05 | +150.0% | 13.22 | +2.1% | -1.7% | -9.2% | -0.1% | +3.5% | -1.1% | — |
| Nov 8, 2024 | AMC | -0.13 | -0.03 | +76.9% | 11.06 | +1.8% | -9.9% | -2.6% | -3.0% | -1.9% | +1.7% | — |
| Aug 5, 2024 | AMC | -0.34 | -0.48 | -41.2% | 8.32 | +1.2% | -4.9% | -1.5% | +3.3% | -3.4% | -4.0% | — |
| May 14, 2024 | AMC | -0.43 | -0.43 | +0.0% | 7.07 | +4.8% | +1.7% | -3.2% | +8.8% | +6.1% | +0.7% | — |
| Mar 26, 2024 | AMC | -0.67 | -0.48 | +28.4% | 4.61 | +2.4% | +10.4% | -6.3% | +0.4% | -1.9% | +3.6% | — |
| Nov 13, 2023 | AMC | -0.51 | -0.61 | -19.6% | 2.98 | -1.0% | -24.5% | +4.9% | +4.7% | -0.8% | +10.2% | — |
| Aug 9, 2023 | AMC | -0.67 | -0.58 | +13.4% | 3.87 | -0.3% | -16.5% | -2.2% | -1.3% | +81.7% | -4.6% | — |
| May 22, 2023 | AMC | -0.57 | -0.77 | -35.1% | 7.05 | +1.4% | +1.6% | +2.8% | +2.6% | +2.1% | +1.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26 | BTIG | Maintains | Buy → Buy | — | $10.21 | $9.43 | -7.6% | -11.9% | -1.1% | +0.3% | -3.7% | +7.3% |
| Jan 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.21 | $10.31 | +1.0% | +1.3% | -0.5% | +1.3% | -0.4% | -1.6% |
| Nov 5 | Stephens & Co. | Maintains | Overweight → Overweight | — | $9.08 | $8.93 | -1.7% | -4.4% | -0.5% | +0.0% | -0.7% | +0.5% |
| Nov 4 | BTIG | Maintains | Buy → Buy | — | $9.52 | $9.08 | -4.6% | -4.6% | -4.4% | -0.5% | +0.0% | -0.7% |
| Oct 21 | Canaccord Genuity | Maintains | Buy → Buy | — | $11.42 | $11.40 | -0.2% | -0.3% | -9.0% | +0.2% | -1.4% | -2.3% |
| Oct 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.97 | $10.54 | -11.9% | -4.6% | -0.3% | -9.0% | +0.2% | -1.4% |
| Aug 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.64 | $10.89 | +2.3% | -4.2% | -1.8% | +5.0% | +3.5% | +2.1% |
| Jun 23 | Stephens & Co. | Maintains | Overweight → Overweight | — | $13.85 | $13.32 | -3.8% | -4.3% | +4.6% | +0.5% | +0.8% | -3.4% |
| May 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.15 | $16.21 | +0.4% | -0.2% | +1.9% | -1.3% | +5.4% | -5.0% |
| Mar 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.22 | $13.50 | +2.1% | -1.7% | -9.2% | -0.1% | +3.5% | -1.1% |
| Jan 17 | Craig-Hallum | Maintains | Buy → Buy | — | $13.67 | $14.00 | +2.4% | +4.7% | +4.7% | +1.5% | +6.0% | -0.8% |
| Jan 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.79 | $12.94 | +1.2% | -0.8% | +0.2% | +7.6% | +4.7% | +4.7% |
| Nov 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.06 | $11.26 | +1.8% | -9.9% | -2.6% | -3.0% | -1.9% | +1.7% |
| Aug 6 | Stephens & Co. | Maintains | Overweight → Overweight | — | $8.32 | $8.42 | +1.2% | -4.9% | -1.5% | +3.3% | -3.4% | -4.0% |
| Aug 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.32 | $8.42 | +1.2% | -4.9% | -1.5% | +3.3% | -3.4% | -4.0% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.07 | $7.41 | +4.8% | +1.7% | -3.2% | +8.8% | +6.1% | +0.7% |
| Mar 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.61 | $4.72 | +2.4% | +10.4% | -6.3% | +0.4% | -1.9% | +3.6% |
| Sep 7 | Canaccord Genuity | Maintains | Buy → Buy | — | $4.71 | $4.86 | +3.2% | -2.3% | +4.6% | +1.9% | -1.8% | -5.8% |
| Aug 16 | Roth MKM | Maintains | Buy → Buy | — | $5.67 | $5.55 | -2.1% | -4.6% | -11.3% | +4.4% | +1.4% | +8.5% |
| Aug 16 | BTIG | Maintains | Buy → Buy | — | $5.67 | $5.55 | -2.1% | -4.6% | -11.3% | +4.4% | +1.4% | +8.5% |
| Aug 15 | Canaccord Genuity | Maintains | Buy → Buy | — | $3.12 | $5.84 | +87.2% | +81.7% | -4.6% | -11.3% | +4.4% | +1.4% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.12 | $5.84 | +87.2% | +81.7% | -4.6% | -11.3% | +4.4% | +1.4% |
| May 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.16 | $7.15 | -0.1% | +2.8% | +2.6% | +2.1% | +1.2% | +2.1% |
| Mar 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.00 | $5.88 | -2.0% | -1.3% | -6.4% | +1.6% | +2.1% | +3.0% |
| Mar 28 | Roth MKM | Maintains | Buy → Buy | — | $6.00 | $5.88 | -2.0% | -1.3% | -6.4% | +1.6% | +2.1% | +3.0% |
| Aug 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.26 | $4.26 | +0.0% | +2.3% | +3.2% | +6.9% | -6.4% | -2.2% |
| Jun 24 | BTIG | Maintains | Buy → Buy | — | $3.88 | $3.63 | -6.4% | +1.0% | +2.3% | +2.2% | -2.7% | +0.0% |
| Dec 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.02 | $8.64 | +7.7% | +5.0% | -4.4% | -5.5% | +8.4% | -1.9% |
| Apr 6 | Roth Capital | Maintains | Buy → Buy | — | $15.10 | $15.20 | +0.7% | -7.9% | +0.7% | -3.1% | +1.6% | -6.5% |
| Mar 9 | Canaccord Genuity | Maintains | Buy → Buy | — | $17.65 | $19.28 | +9.2% | +10.4% | -3.2% | +1.2% | -1.0% | +0.3% |
| Jan 5 | BTIG | Maintains | Buy → Buy | — | $16.91 | $16.80 | -0.7% | +1.2% | +1.2% | +5.8% | -5.6% | -2.9% |
| Nov 25 | Roth Capital | Maintains | Buy → Buy | — | $17.16 | $17.95 | +4.6% | -1.7% | -0.1% | -0.6% | -5.4% | +0.9% |
| Jun 4 | Roth Capital | Maintains | Buy → Buy | — | $7.75 | $7.80 | +0.6% | +1.3% | +1.1% | +0.8% | +0.0% | +1.9% |
| Mar 4 | Wallachbeth | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| May 3 | JMP Securities | Downgrade | Market Outperform → Perform | — | — | — | — | — | — | — | — | — |
| May 3 | Roth Capital | Downgrade | Buy → Sell | — | — | — | — | — | — | — | — | — |
| May 3 | Cowen & Co. | Downgrade | Outperform → Underperform | — | — | — | — | — | — | — | — | — |
| May 3 | Wedbush | Downgrade | Outperform → Neutral | — | — | — | — | — | — | — | — | — |
| Mar 15 | Wedbush | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| Jun 4 | Canaccord Genuity | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
No insider trades available.
8-K
Delcath Systems Inc -- 8-K Filing
Delcath Systems' percutaneous hepatic perfusion combined with ipilimumab and nivolumab showed promising results for metastatic uveal melanoma in the published CHOPIN Phase 2 trial, potentially supporting future development and commercialization efforts.
Mar 3
8-K
Delcath Systems Inc -- 8-K Filing
Delcath Systems reported its fourth quarter and full year 2025 financial results, with management hosting a conference call to discuss performance and outlook for the medical device company.
Feb 26
8-K · 5.02
!!! Very High
Nuwellis, Inc. -- 8-K 5.02: Executive Change
Nuwellis appointed Martin J. Emerson and David A. McDonald as Class I directors, potentially signaling board refreshment and strategic changes for the medical device company's governance structure.
Feb 26
Data updated apr 25, 2026 4:49am
· Source: massive.com